Recent Progress, Vaccine Institute Of Microbiology From China Declared Safe For Humans

Photo illustration (Source: Antara)

JAKARTA - The Chinese Academy of Sciences (CAS) claims the COVID-19 vaccine developed by the Institute of Microbiology is safe for humans. This belief was obtained based on the results of clinical trials by the institution.

The results of the phase I and phase II trials have resulted in safety and health for people who receive the vaccine injection. The trials also showed no serious side effects.

Institute of Microbiology, an institution under CAS is working with Congqing Zhifei Biological Products Co Ltd in vaccine development. They have obtained development permits from China's National Medical Products Agency (NMPA) on June 19.

Researchers began conducting clinical trials on June 23 to make sure the vaccine is safe to administer to humans. Volunteers aged 18-59 years. They came from Beijing, Chongqing, and Hunan.

Volunteers receive injections at hospitals in Beijing and Chongqing. Then, a second clinical trial was conducted on July 10 to evaluate the immunity power and safety of the vaccine.

According to the development agency, randomized clinical trials are conducted to determine the effectiveness of vaccines before they are mass produced. The vaccine is patented and the developer has prepared a phase III clinical trial to confirm the vaccine's efficacy.

To date, in China there have been 13 COVID-19 vaccines developed by several research institutes and pharmaceutical manufacturers. The Chinese Ministry of Science and Technology said that there were already four COVID-19 vaccine candidates that had carried out phase III clinical trials.

Chinese people are looking forward to the vaccine. Sinovac and Sinopharm, China's largest vaccine company, recently started offering a limited amount via online platforms.